Company
L1 Therapeutics develops precision therapies targeting LINE-1, an ancient virus-like retrotransposon element in the human genome that reactivates under stress and contributes to disease. The company focuses on conditions where active LINE-1 biology drives genomic instability and innate immune dysfunction, particularly in oncology and age-related diseases. L1 also offers open-source software tools for detecting LINE-1 insertions in genomic sequencing data.
L1 Therapeutics is a privately held company. Leadership tracked by CEOInsider includes William Brandler (CEO).
Current
Our coverage
Inspired by Nobel laureate Barbara McClintock, the scientist-engineer behind L1 Therapeutics is combining genomics, open-source software and AI-assisted development to pursue one of medicine’s harder…
Recent coverage of L1 Therapeutics has centered on scientific research related to PD-L1 imaging and immunotherapy, including PET imaging approaches for assessing PD-L1 occupancy in combined treatment strategies and the broader landscape of PD-1/PD-L1 imaging tracers. The headlines also reflect peer-reviewed studies examining spatial heterogeneity of PD-L1 expression in cancer, pharmacodynamic measures of PD(L)-1 antibody therapeutics, and combination immunotherapy approaches in lymphoma and leukemia.
Summarized from the headlines in the sidebar; see each source for the full story.